CRCU

Chemical Research in Chinese Universities ›› 2006, Vol. 22 ›› Issue (2): 245-247.

• Articles • Previous Articles     Next Articles

Inhibition of Metalloproteinase Activity by Chinese Formulations Used to Treat Inflammatory Diseases

JIN Feng-hai1,2, WANG Hui-ling1,3, ZHAO Shu-hua4, YANG Jin-gang1, FANG Xue-xun1   

  1. 1. Key Laboratory of Molecular Enzymology and Engineering, the Ministry of Education, Jilin University, Changchun 130021, P.R.China;

    2. School of Pharmacy, Jilin University, Changchun 130021, P.R.China;

    3. College of Life Science, Jilin University, Changchun 130021, P.R.China;

    3. The China-Japan Union Hospital, Jilin University, Changchun 130021, P.R.China
  • Received:2005-12-31 Online:2006-04-24 Published:2011-08-06
  • Supported by:

    Supported by the National Natural Science Foundation of China(No.30371656) and Jilin Distinguished Young Scholars Program Grant Award(No.6-21-10).

PDF (PC)

Cited

16

Abstract: Matrix metalloproteinases (MMPs) are known to be involved in a number of pathological processes including cancer, atherosclerosis, arthritis and neurodegenerative disease among others.The drive to develop MMP inhibitors as therapeutics has been put forward for years by pharmaceutical companies as well as academicians.In an attempt to screen for MMP inhibitors from Traditional Chinese Medicines (TCMs), a number of Chinese formulations used to treat inflammatory diseases such as nephritis and hepatitis have been studied.Strong inhibitory effects of three Chinese formulations toward the activity of MMP-16 have been discovered.These results suggest that these anti-inflammatory medicines contain some unknown MMP inhibitory compound(s) and provide reasonable molecular mechanisms for their therapeutic effects.

Key words: Matrix metalloproteinase (MMP), Matrix metalloproteinase inhibitor (MMPI), Traditional ChineseMedicine (TCM), Herbal formulation